Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Long COVID clinical trials

Directory of U.S. ClinicalTrials.gov public records for Long COVID. Browse Long COVID recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
222
Shown on this page
12
Local recruiting
27
Local phase groups
4

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Long COVID studies are organized in the registry

Terminology for this condition is unusually inconsistent across the registry: the same kind of study may be filed under “long COVID,” “post-acute sequelae of SARS-CoV-2,” the abbreviation PASC, or “post-COVID conditions.” Trying more than one of these terms is the single most effective way to avoid missing records.

  • 69% of the 39 locally indexed Long COVID records are currently marked recruiting.
  • The most common phase group in the local index is Not applicable (15 records).
  • The most frequent sponsor is Icahn School of Medicine at Mount Sinai (4 records).
  • The most listed study location is Boston, Massachusetts (6 records).
Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Long COVID. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 222 matching trials for Long COVID.
Live ClinicalTrials.gov results.

Live official records

Open in full search
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Keytruda
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Post-Concussion Syndrome, COVID Long-Haul, COVID-19
Interventions
percutaneous electrical nerve-field stimulation, PENFS, percutaneous electrical nerve-field stimulation, PENFS (sham device), percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
Device
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
11 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Cypress, California • Lenexa, Kansas • Salt Lake City, Utah
Conditions
Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Recruiting Phase 2 Interventional

LIFT: Life Improvement Trial

NCT06366724
Conditions
ME/CFS, Long COVID, PASC
Interventions
Pyridostigmine, Low-Dose Naltrexone, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions
IV normal saline, IV immunoglobulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Pediatric COVID Outcomes Study (PECOS)

NCT04830852
Conditions
Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Years to 21 Years
Enrollment
1,097 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Completed Phase 2Phase 3 Interventional Results available

Fluvoxamine for Long COVID-19

NCT05874037
Conditions
Long COVID
Interventions
Fluvoxamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Structured Pacing, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Long COVID
Interventions
Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
Douglas D. Fraser
Other
Eligibility
18 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California

About this Long COVID clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Long COVID as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Long COVID.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Long COVID.